NanoViricides (NYSE:NNVC) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC) in a research report released on Monday morning. The brokerage issued a sell rating on the stock.

NanoViricides Trading Up 0.9 %

NanoViricides stock opened at $1.17 on Monday. NanoViricides has a 1-year low of $1.00 and a 1-year high of $2.00. The firm has a market capitalization of $13.78 million, a price-to-earnings ratio of -1.44 and a beta of 0.67. The firm’s fifty day moving average price is $1.22 and its two-hundred day moving average price is $1.16.

NanoViricides (NYSE:NNVC) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. UBS Group AG lifted its position in shares of NanoViricides by 114.5% during the first quarter. UBS Group AG now owns 17,448 shares of the company’s stock valued at $37,000 after purchasing an additional 9,314 shares in the last quarter. Two Sigma Securities LLC bought a new position in shares of NanoViricides during the second quarter valued at about $28,000. Northern Trust Corp lifted its position in shares of NanoViricides by 60.4% during the fourth quarter. Northern Trust Corp now owns 29,664 shares of the company’s stock valued at $30,000 after purchasing an additional 11,170 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of NanoViricides during the third quarter valued at about $59,000. Finally, Millennium Management LLC lifted its position in shares of NanoViricides by 59.1% during the fourth quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock valued at $75,000 after purchasing an additional 25,012 shares in the last quarter. 10.30% of the stock is owned by institutional investors.

NanoViricides Company Profile

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.